Company news

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) news

Lixte Biotechnology Holdings, Inc. news releases on 6ix. Latest, Mar 27, 2025: LIXTE Biotechnology Provides Update On Progress with Proprietary Compound…

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) news

Press releases — page 2

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form

LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

LIXTE Biotechnology Provides Update On Recent Activities and Developments

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

LIXTE Biotechnology Holdings Provides Update on Recent Activities

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas

LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023

LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma

LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer

LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS

LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS

LIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug Combinations

LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market

Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100

LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE’S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORS

Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment

Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction

LIXTE BIOTECHNOLOGY’S LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPORTANT PRE-CLINICAL STUDY

Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer

LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THE APPOINTMENT OF REGINA BROWN TO ITS BOARD OF DIRECTORS

Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of Directors

Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference

Lixte Biotechnology Announces the Closing of $4.19 Million Registered Direct Offering

Lixte Biotechnology Announces $4.19 Million Registered Direct Offering

Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences Conference

Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer

Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq

Lixte Biotechnology Holdings, Inc. Announces Pricing of $5,700,000 Public Offering; Uplisting to Nasdaq Capital Market and Reverse Stock Split

Lixte Biotechnology Holdings, Inc. Announces The Appointment Of Internationally Recognized Clinical Cancer Investigator, James S. Miser MD, As Chief Medical Officer